Structural and functional alterations in the surface of vascular endothelial cells associated with the formation of a confluent cell monolayer and with the withdrawal of fibroblast growth factor.
Vascular endothelial cells cultured in the presence of fibroblast growth factor (FGF) divide actively when seeded at low or clonal cell densities and upon reaching confluence adopt a morphologic appearance and differentiated properties similar to those of the vascular endothelium in vivo. In this review, we present some of our recent observations regarding the characteristics (both structural and functional) of these endothelial cells and the role of FGF in controlling their proliferation and normal differentiation. At confluence the endothelial cells form a monolayer of closely apposed and nondividing cells that have a nonthrombogenic apical surface and can no longer internalize bound ligands such as low-density lipoprotein (LDL). The adoption of these properties is correlated and possibly causally related to changes in the cell surface such as the appearance of a 60,000 molecular weight protein (CSP-60); the disappearance of fibronectin from the apical cell surface and its concomitant accumulation in the basal lamina; and a restriction of the lateral mobility of various cell surface receptor sites. In contrast, endothelial cells that are maintained in the absence of FGF undergo within three passages alterations that are incompatible with their in vivo morphologic appearance and physiologic behavior. They grow at confluence on top of each other and hence can no longer adopt both the structural (CSP-60, cell surface polarity) and functional (barrier function, nonthrombogenicity) attributes of differentiated endothelial cells. Since these characteristics can be reacquired in response to readdition of FGF, in addition to being a mitogen FGF may also be involved in controlling the differentiation and phenotypic expression of the vascular endothelium.
D000818:Animals; D001011:Aorta / Q000502:physiology; D002417:Cattle; D002455:Cell Division; D002478:Cells, Cultured; D003470:Culture Media; D004727:Endothelium / Q000187:drug effects / Q000502:physiology; D005346:Fibroblast Growth Factors; D005455:Fluorescent Antibody Technique; D006131:Growth Inhibitors / Q000494:pharmacology*; D006321:Heart / Q000502:physiology; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000503:physiopathology*; D010455:Peptides / Q000494:pharmacology*; D010907:Pituitary Hormones / Q000494:pharmacology*
D003470:Culture Media; D006131:Growth Inhibitors; D008077:Lipoproteins, LDL; D010455:Peptides; D010907:Pituitary Hormones; D005346:Fibroblast Growth Factors